Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Why Enliven’s FDA alignment may matter as ELVN-001 moves toward Phase 3 Find out how Enliven’s ELVN-001 data and FDA alignment could reshape the next phase of chronic myeloid leukemia therapy. byPallavi MadhirajuJune 12, 2026